share_log

Investors Are Selling off Guangzheng Eye Hospital Group (SZSE:002524), Lack of Profits No Doubt Contribute to Shareholders Three-year Loss

Investors Are Selling off Guangzheng Eye Hospital Group (SZSE:002524), Lack of Profits No Doubt Contribute to Shareholders Three-year Loss

投資者拋售光正眼科醫院集團(深交所股票代碼:002524),利潤不足無疑導致股東三年虧損
Simply Wall St ·  2023/10/24 02:09

Many investors define successful investing as beating the market average over the long term. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term Guangzheng Eye Hospital Group Co., Ltd. (SZSE:002524) shareholders have had that experience, with the share price dropping 47% in three years, versus a market decline of about 13%. The last week also saw the share price slip down another 13%. This could be related to the recent financial results - you can catch up on the most recent data by reading our company report.

許多投資者將成功的投資定義為長期超過市場平均水準。但選股的風險是,你可能會買入表現不佳的公司。我們很遺憾地報告這一長期的光正眼科醫院集團有限公司。(SZSE:002524)股東有過這樣的經歷,股價在三年內下跌了47%,而市場跌幅約為13%。上週,該公司股價又下跌了13%。這可能與最近的財務業績有關-您可以通過閱讀我們的公司報告來了解最新的數據。

With the stock having lost 13% in the past week, it's worth taking a look at business performance and seeing if there's any red flags.

鑑於該公司股價在過去一週下跌了13%,我們有必要看看它的業務表現,看看是否有任何危險信號。

See our latest analysis for Guangzheng Eye Hospital Group

查看我們對光正眼科醫院集團的最新分析

Given that Guangzheng Eye Hospital Group didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

鑑於光正眼科醫院集團在過去12個月中沒有盈利,我們將重點關注收入增長,以快速瞭解其業務發展。未盈利公司的股東通常預期營收增長強勁。正如你可以想像的那樣,快速的收入增長,如果保持下去,往往會帶來快速的利潤增長。

Over the last three years, Guangzheng Eye Hospital Group's revenue dropped 4.1% per year. That is not a good result. The annual decline of 14% per year in that period has clearly disappointed holders. That makes sense given the lack of either profits or revenue growth. Of course, sentiment could become too negative, and the company may actually be making progress to profitability.

在過去的三年裡,光正眼科醫院集團的收入每年下降4.1%。這不是一個好結果。在此期間,每年14%的跌幅顯然讓持有者感到失望。考慮到既沒有利潤也沒有收入增長,這是有道理的。當然,市場情緒可能會變得過於負面,該公司實際上可能正在盈利方面取得進展。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下圖中看到收益和收入隨時間的變化(單擊圖表查看確切的值)。

earnings-and-revenue-growth
SZSE:002524 Earnings and Revenue Growth October 24th 2023
深交所:2023年10月24日收益和收入增長002524

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

資產負債表的強健至關重要。也許很值得一看我們的免費報告其財務狀況如何隨著時間的推移而發生變化。

A Different Perspective

不同的視角

We regret to report that Guangzheng Eye Hospital Group shareholders are down 15% for the year. Unfortunately, that's worse than the broader market decline of 6.4%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 7%, each year, over five years. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For instance, we've identified 1 warning sign for Guangzheng Eye Hospital Group that you should be aware of.

我們遺憾地報告,光正眼科醫院集團股東今年以來下跌了15%。不幸的是,這比大盤6.4%的跌幅還要糟糕。話雖如此,在下跌的市場中,一些股票不可避免地會被超賣。關鍵是要密切關注基本面的發展。較長期的投資者不會如此沮喪,因為他們在五年內每年會獲得7%的收益。最近的拋售可能是一個機會,因此可能值得查看基本面數據,以尋找長期增長趨勢的跡象。雖然值得考慮市場狀況對股價可能產生的不同影響,但還有其他更重要的因素。例如,我們已經確定廣正眼科醫院集團1塊警示牌這一點你應該知道.

We will like Guangzheng Eye Hospital Group better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我們看到一些大的內部收購,我們會更喜歡光正眼科醫院集團。在我們等待的時候,看看這個免費最近有大量內幕收購的成長型公司名單.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫.或者,也可以給編輯組發電子郵件,地址是暗示Wallst.com。
本文由Simply Wall St.撰寫,具有概括性.我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議.它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況.我們的目標是為您帶來由基本面數據驅動的長期重點分析.請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內.Simply Wall St.對上述任何一隻股票都沒有持倉.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論